Psoriasis

The US Food and Drug Administration has granted approval to a foam treatment for plaque psoriasis in adolescents.

The US Food and Drug Administration has approved expanding the label of a psoriasis drug to include adults with moderate-to-severe plaque psoriasis.

The FDA has approved a label update for a biologic used for the treatment of adult patients with moderate-to-severe plaque psoriasis

Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.

The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a biologic therapy for the treatment of patients with moderate to severe plaque psoriasis.

The FDA approved the injection Siliq (brodalumab) to treat adults with moderate to severe plaque psoriasis.

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.